In vivo PDX CRISPR/Cas9 screens reveal mutual therapeutic targets to overcome heterogeneous acquired chemo-resistance. - Wirth AK; Wange L; Vosberg S; Henrich KO; Rausch C; Özdemir E; Zeller CM; Richter D; Feuchtinger T; Kaller M; Hermeking H; Greif PA; et al. (Leukemia, 2022)